Read More Pharma Industry News Cognition Therapeutics reports promising Phase 2 results for CT1812 in dementia with Lewy bodies Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage pharmaceutical company focused on neurodegenerative disorder treatment, has reported highly encouraging… byPallavi MadhirajuDecember 18, 2024